Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.

Shivaani Kummar,Cornelis M. van Tilburg,Catherine M. Albert,Jordan Berlin,Anna F. Farago,Raymond S. McDermott,Stefan S. Bielack,F. Doz,Steven G. DuBois,Ulrik Lassen,Serge Leyvraz,Leo Mascarenhas,Ramamoorthy Nagasubramanian,Karen N. Keating,Costel Chirila,Barrett H. Childs,Theodore W. Laetsch,Alexander Drilon,David S. Hong

Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.

2020

Shivaani Kummar
Cornelis M. van Tilburg
Catherine M. Albert
Jordan Berlin
Anna F. Farago
Raymond S. McDermott
Stefan S. Bielack
F. Doz
Steven G. DuBois
Ulrik Lassen
Serge Leyvraz
Leo Mascarenhas
Ramamoorthy Nagasubramanian
Karen N. Keating
Costel Chirila
Barrett H. Childs
Theodore W. Laetsch
Alexander Drilon
David S. Hong

3614Background: NTRK gene fusions occur in diverse tumor types in adults and children. The selective TRK inhibitor, larotrectinib, has shown high response rates, durable disease control, and a favo...

Keywords:

Cancer
Oncology
Physical therapy
Trk receptor
Quality of life
Population
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations